文献速递淋巴瘤

大B细胞淋巴瘤嵌合抗原受体(CAR)T细胞治疗失败后的结局

Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
PubMed 文献 · Br J Haematol · 2023-09-10

该回顾性研究评估了51例大B细胞淋巴瘤患者在接受阿基仑赛或替沙仑赛治疗失败后接受挽救治疗的结局。22例(43%)入组临床试验,29例接受标准治疗或支持治疗。中位随访11.7个月时,估计12个月总生存率为35%,对CAR T细胞治疗无反应和诊断非PMBCL及t-FL是预后不良因素。

要点

  • CAR T细胞治疗失败后患者预后差,12个月总生存率仅35%。
  • 对CAR T细胞治疗无反应者死亡风险增高(HR 3.08)。
  • 诊断非PMBCL及t-FL者预后更差(HR 4.54)。

核心结论

  • CAR T细胞治疗失败的患者结局差,需进一步研究。

研究设计与样本

  • 回顾性评估51例因复发/难治性大B细胞淋巴瘤接受阿基仑赛或替沙仑赛治疗失败后挽救治疗的结局。

主要发现

  • 22例(43%)入组临床试验(glofitamab或loncastuximab tesirine联合ibrutinib),29例接受标准治疗(来那度胺、检查点抑制剂、ibrutinib、化学免疫治疗和放疗)或支持治疗。
  • 39例接受治疗的患者中26例(67%)接受基于免疫的治疗(glofitamab、CPI、Len),其中以双特异性抗体为主(n=18)。
  • 中位随访11.7个月时,估计12个月总生存率为35%。
  • 多变量模型中,对CAR T细胞治疗无反应(HR 3.08;p=0.0109)和诊断非PMBCL及t-FL(HR 4.54;p=0.0069)是不良预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B-cell lymphomas. Of these patients, 22 (43%) were enrolled in clinical trials (glofitamab or loncastuximab tesirine + ibrutinib), whereas 29 received standard therapies (lenalidomide [Len], checkpoint inhibitors [CPIs], ibrutinib [I], chemoimmunotherapy and radiotherapy) or supportive care. Overall, 26 of 39 (67%) treated patients received a treatment based on immunotherapy (glofitamab, CPI, Len) that was mainly represented by bispecific antibody (n = 18). In this subgroup, plasma samples were collected and analysed for circulating tumour DNA (ctDNA) using cancer-personalized profiling by deep sequencing (CAPP-seq). The study found that patients with high ctDNA had poor outcomes. At a median follow-up of 11.7 months, the estimated 12-month overall survival (OS) was 35%. Factors adversely affecting the prognosis in the multivariable model were the absence of response to CAR T-cell therapy (HR: 3.08; p = 0.0109) and a diagnosis other than PMBCL and t-FL (HR: 4.54; p = 0.0069). The outcome of patients failing CAR T cells is poor and requires further investigation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dodero A, Bramanti S, Di Trani M, et al. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas. Br J Haematol. 2023. PMID: 37690811. doi:10.1111/bjh.19057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。